Genzyme (GENZ) investors might be forgiven for doing a double-take last week when they saw the following headline: Genzyme Laboratory Recognized for Quality.
After all, the words "Genzyme" and "quality" aren't often seen in close quarters these days, not unless the sentence also includes words like "abysmal" or "fiasco."
Which is why it was ironic to see Genzyme patting itself on the back with a press release about a quality award.
To be fair, the award had nothing to do with the Allston manufacturing plant. Genzyme's genetic testing laboratory in Phoenix, Arizona gained accreditation from the College of American Pathologists. It's apparently the first commercial genetic testing facility to achieve those honors, which are based on technical competence and quality management.
According to the release:
"Achieving this accreditation demonstrates our commitment to achieving superior quality standards and delivering overall operational excellence," said Jon Hart, senior vice president and general manager of Genzyme Genetics.Well, at least someone, somewhere in the Genzyme organization is on the ball when it comes to quality. Think they're interested in a transfer to Allston?